Keyphrases
Activated T Cells
11%
Adverse Events
11%
Airway Inflammation
11%
Asthma
11%
Asthma Control
100%
Asthma Symptoms
11%
Between-group
11%
CD25
11%
CD25+
11%
Clinical Trials
11%
Daclizumab
100%
Disease Duration
11%
Equivalent Dose
11%
Evenly Distributed
11%
Forced Expiratory Volume in 1 Second (FEV1)
11%
Function Control
11%
Humanized
11%
Inflammatory Cytokines
11%
Inhaled Corticosteroid Therapy
11%
Inhaled Corticosteroids
33%
Interleukin-2
11%
Loading Dose
11%
Mechanism of Action
11%
Moderate to Severe
100%
Placebo
22%
Placebo Groups
11%
Placebo-controlled Study
11%
Pulmonary Function
11%
Randomized Controlled Trial
100%
Serious Adverse Events
11%
Severe Persistent Asthma
100%
Short-acting
11%
Soluble interleukin-2 Receptor (sIL-2R)
33%
Stable Dose
11%
T Cells
11%
Treatment Duration
33%
Triamcinolone Acetonide
33%
Medicine and Dentistry
Adverse Event
22%
Asthma
100%
Clinical Trial
11%
Cytokine
11%
Daclizumab
100%
Disease Duration
11%
Immunoglobulin G1
11%
Loading Drug Dose
11%
Lung Function
22%
Lymphocyte
11%
Monoclonal Antibody
11%
Placebo
33%
Placebo-Controlled Study
11%
Randomized Controlled Trial
100%
Respiratory Tract Inflammation
11%
Severe Persistent Asthma
100%
Symptom
11%
T Cell
22%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
22%
Asthma
100%
Clinical Trial
11%
Cytokine
11%
Disease Duration
11%
Immunoglobulin G1
11%
Monoclonal Antibody
11%
Placebo
33%
Placebo-Controlled Study
11%
Randomized Controlled Trial
100%
Respiratory Tract Inflammation
11%
Severe Persistent Asthma
100%
Symptom
11%